Università della Svizzera italiana

Targeting the DNA damage response for patients with lymphoma : preclinical and clinical evidences

Carrassa, Laura ; Colombo, Ilaria ; Damia, Giovanna ; Bertoni, Francesco

In: Cancer treatment reviews, 2020, vol. 90, p. 11

The DNA damage response (DDR) is a well-coordinated cellular network activated by DNA damage. The unravelling of the key players in DDR, their specific inactivation in different tumor types and the synthesis of specific chemical inhibitors of DDR represent a new hot topic in cancer therapy. In this article, we will review the importance of DDR in lymphoma development and how this can be...

Università della Svizzera italiana

Retinoic acid sensitivity of triple-negative breast cancer cells characterized by constitutive activation of the NOTCH1 pathway : the role of RARβ

Paroni, Gabriela ; Zanetti, Adriana ; Barzago, Maria Monica ; Kurosaki, Mami ; Guarrera, Luca ; Fratelli, Maddalena ; Troiani, Martina ; Ubezio, Paolo ; Bolis, Marco ; Vallerga, Arianna ; Biancardi, Federica ; Terao, Mineko ; Garattini, Enrico

In: Cancers, 2020, vol. 12, no. 10, p. 23 p

Triple-negative breast cancer (TNBC) is a heterogeneous disease that lacks effective therapeutic options. In this study, we profile eighteen TNBC cell lines for their sensitivity to the anti-proliferative action of all-trans retinoic acid (ATRA). The only three cell lines (HCC-1599, MB- 157 and MDA-MB-157) endowed with ATRA-sensitivity are characterized by genetic aberrations of the NOTCH1-gene,...

Università della Svizzera italiana

CD49d promotes disease progression in chronic lymphocytic leukemia : new insights from CD49d bimodal expression

Tissino, Erika ; Pozzo, Federico ; Benedetti, Dania ; Caldana, Chiara ; Bittolo, Tamara ; Rossi, Francesca Maria ; Bomben, Riccardo ; Nanni, Paola ; Chivilò, Hillarj ; Cattarossi, Ilaria ; Zaina, Eva ; Norris, Kevin ; Polesel, Jerry ; Gentile, Massimo ; Tripepi, Giovanni ; Moia, Riccardo ; Santinelli, Enrico ; Innocenti, Idanna ; Olivieri, Jacopo ; D’Arena, Giovanni ; Laurenti, Luca ; Zaja, Francesco ; Pozzato, Gabriele ; Chiarenza, Annalisa ; Di Raimondo, Francesco ; Rossi, Davide ; Pepper, Chris ; Hartmann, Tanja Nicole ; Gaidano, Gianluca ; Del Poeta, Giovanni ; Gattei, Valter ; Zucchetto, Antonella

In: Blood, 2020, vol. 135, no. 15, p. 1244–1254

CD49d is a remarkable prognostic biomarker of chronic lymphocytic leukemia (CLL). The cutoff value for the extensively validated 30% of positive CLL cells is able to separate CLL patients into 2 subgroups with different prognoses, but it does not consider the pattern of CD49d expression. In the present study, we analyzed a cohort of 1630 CLL samples and identified the presence of ∼20% of CLL...

Università della Svizzera italiana

Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia

Diop, Fary ; Moia, Riccardo ; Favini, Chiara ; Spaccarotella, Elisa ; De Paoli, Lorenzo ; Bruscaggin, Alessio ; Spina, Valeria ; Terzi-di-Bergamo, Lodovico ; Arruga, Francesca ; Tarantelli, Chiara ; Deambrogi, Clara ; Rasi, Silvia ; Adhinaveni, Ramesh ; Patriarca, Andrea ; Favini, Simone ; Sagiraju, Sruthi ; Jabangwe, Clive ; Kodipad, Ahad A. ; Peroni, Denise ; Mauro, Francesca R. ; Del Giudice, Ilaria ; Forconi, Francesco ; Cortelezzi, Agostino ; Zaja, Francesco ; Bomben, Riccardo ; Rossi, Francesca Maria ; Visco, Carlo ; Chiarenza, Annalisa ; Rigolin, Gian Matteo ; Marasca, Roberto ; Coscia, Marta ; Perbellini, Omar ; Tedeschi, Alessandra ; Laurenti, Luca ; Motta, Marina ; Donaldson, David ; Weir, Phil ; Mills, Ken ; Thornton, Patrick ; Lawless, Sarah ; Bertoni, Francesco ; Del Poeta, Giovanni ; Cuneo, Antonio ; Follenzi, Antonia ; Gattei, Valter ; Boldorini, Renzo Luciano ; Catherwood, Mark ; Deaglio, Silvia ; Foà, Robin ; Gaidano, Gianluca ; Rossi, Davide

In: Haematologica, 2020, vol. 105, no. 2, p. 448-456

BIRC3 is a recurrently mutated gene in chronic lymphocytic leukemia (CLL) but the functional implications of BIRC3 mutations are largely unexplored. Furthermore, little is known about the prognostic impact of BIRC3 mutations in CLL cohorts homogeneously treated with first-line fludarabine, cyclophosphamide, and rituximab (FCR). By immunoblotting analysis, we showed that the non-canonical...